Gilead Sciences Inc
XHAM:GIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Gilead Sciences Inc
XHAM:GIS
|
US |
|
Innate Pharma SA
F:IDD
|
FR |
Wall St Price Targets
GIS Price Targets Summary
Gilead Sciences Inc
According to Wall Street analysts, the average 1-year price target for
GIS is 143.26 EUR with a low forecast of 109.42 EUR and a high forecast of 167.83 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GIS's stock price target?
Price Target
143.26
EUR
According to Wall Street analysts, the average 1-year price target for
GIS is 143.26 EUR with a low forecast of 109.42 EUR and a high forecast of 167.83 EUR.
What is the Revenue forecast for Gilead Sciences Inc?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 4%.
What is the Gross Profit forecast for Gilead Sciences Inc?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for Gilead Sciences Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 8 years is 8%.
What is the Pre-Tax Income forecast for Gilead Sciences Inc?
Projected CAGR
19%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 8%. The projected CAGR for the next 3 years is 19%.
What is the Net Income forecast for Gilead Sciences Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 8 years is 9%.